$Virios Therapeutics (VIRI.US)$ November 2, 2023 Dear Virios...

November 2, 2023

Dear Virios (VIRI) Shareholders,

We wanted to provide you with a succinct corporate progress report as we exit the third quarter of 2023, which can be summarized as follows:

●

Having secured FDA guidance on our plan to progress IMC-1 to Phase 3 development to treat fibromyalgia, we can convey that several life science companies are engaged and reviewing our Phase 2 data and proposed Phase 3 program as the basis for a potential forward development partnership.

●

We have submitted briefing materials to the FDA concerning submission of a proposed investigational new drug application for IMC-2 as a treatment for Long-COVID (“LC”).

❖

There are currently no FDA approved LC treatments.

●

Filed new provisional method-of-use intellectual property protection for IMC-2 as treatment for LC and Alzheimer’s disease, which if granted, provides coverage to at least 2043.

●

Through prudent expense management, the Company expects to have capital to support operations into Q3 of 2024.

Warmest regards,

Greg Duncan

Chairman & CEO Virios Therapeutics, Inc.